IMI to Boost Patient Involvement in its Activities

Innovative Medicines InitiativeThe Innovative Medicines Initiative (IMI) is creating a 'pool' of patient experts to strengthen the role and voice of patients in IMI activities at both strategic and operational levels. IMI has always involved patients in its work; now the plan is to take patient engagement at IMI to the next level.

IMI has involved patients in its projects and activities since the very beginning - as project partners, as members of the IMI Scientific Committee, and as speakers in our events, for example. Now, IMI wants to enhance the involvement of patients in all activities, for example by inviting them to provide input on scientific strategies; review project proposals; and assess the results of ongoing and closed projects.

To facilitate this, IMI is establishing a pool of patient experts that is open to a wide range of patients (and family members and carers) with a chronic illness or condition that is linked to IMI’s Strategic Research Agenda. The conditions for being part of the pool are simple and people who are interested in getting involved can submit an expression of interest via the IMI website.

When registering their interest, patients will be asked about their knowledge and experience of medical research and drug development, among other things. Whenever IMI has a task or activity that would benefit from patient input, the IMI Programme Office will turn to the pool to find the patient(s) with the most relevant knowledge and experience. For all tasks, patients will act in their personal capacity.

IMI Executive Director Dr Pierre Meulien said: "Patient engagement has always been a priority for IMI, and I am convinced that patients can and should be actively involved as equal partners in medical research and innovation. I hope that this pool of patient experts will provide both patients with a channel to influence research into their disease or condition, and IMI with information that will allow us to deliver projects that are truly aligned with patients’ needs."

Benefits for patients of getting involved in this new initiative include the opportunity to influence IMI’s activities on both strategic and operational levels; work alongside experts from other sectors (academia, industry, regulatory, etc.); raise the profile of patients as equal partners in research in the IMI community and beyond; and learn first-hand about the latest research developments in their disease area.

More information on the criteria for inclusion in the pool, how to apply, and the kinds of tasks participants could expect to be involved in, can be found in via this web page.

Deadline for submitting expressions of interest: 16 July 2019 at 17:00 CEST (Central European Summer Time / Brussels time)

IMI will hold a webinar for people interested in joining the pool on Tuesday 18 June at 14:00 CEST. Registration is free but obligatory via this link.

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Novartis and Microsoft Announce Collabor…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The...

Guerbet and IBM Watson Health Announce a…

Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, announced that it has signed a new agreement with IBM Watson Health to co-develop and...

Bayer Inks Deals with Eleven Startups un…

Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup companies aiming for longer-term collaborations...

Orion Health Delivers the First Health I…

The first Health Information Exchange (HIE) in the Middle East, Malaffi, went live at the end of July just six months after contracts were signed between the project company, Abu...

Joined Up Health and Care 2019 to Explor…

Professionals from across the country will come together to seek real answers on how to deliver closely integrated services, as the Joined Up Health and Care conference returns for its...

IMS MAXIMS Wins Healthcare Innovation Aw…

Health technology specialist IMS MAXIMS has been recognised for its innovative work in the UK and Irish healthcare market in the 2019 CV Business Innovator Awards. The company has been...

Health Tech Marketing and PR Agency Incr…

Highland Marketing, a full service agency for health techmarketing, PR and communications, has appointed Tia Dissanayake to a new account executive role,in which she will support the team withher life...

Brain-Computer Interfaces without the Me…

It sounds like science fiction: controlling electronic devices with brain waves. But researchers have developed a new type of electroencephalogram (EEG) electrode that can do just that, without the sticky...

Up-Close and Personal with Neuronal Netw…

How our brain cells, or neurons, use electrical signals to communicate and coordinate for higher brain function is one of the biggest questions in all of science. For decades, researchers...

Almirall Takes a Leap into Dermatology D…

Almirall, S.A. (ALM) has launched its first call for innovation to start-ups focused on dermatology digital health. This initiative is the first step in the creation of an accelerator programme...